Gebo Biotech announced today that it has received a strategic equity investment of 30 million US dollars from Sanofi. This round of investment will support the development and development of GB Biotech's two core projects, GLB-005 and GLB-007. Both drugs are expected to become disease-modifying treatments for sickle cell disease.

Gebo Biotech announced today that it has received a strategic equity investment of 30 million US dollars from Sanofi. This round of investment will support the development and development of GB Biotech's two core projects, GLB-005 and GLB-007. Both drugs are expected to become disease-modifying treatments for sickle cell disease.